Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists

This article was originally published here

It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the research and

The post Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply